



SomnoMed Board appointment

9th November 2020, Sydney: SomnoMed Limited (ASX SOM) announced today Karen Borg will join the Board of Directors.

Karen will join the Board as a non-executive Director on 26th November 2020 and will be nominated for re-election at the next general meeting of shareholders subsequent to that date.

“It gives me great pleasure to welcome Karen to the board of SomnoMed Limited. Karen has many years of national and international experience in the medical device and healthcare industry. I am confident that Karen will be able to contribute greatly to the future global development of our company,” said Mr Guy Russo, Chairman of SomnoMed Limited.

Further information on Karen Borg is provided below.

Karen Borg Background

Karen has multi-sector, market and channel experience in multiple industries in FTSE100-250 companies. She has led organisational transformation and commercial growth in emerging and mature markets in Asia/Pacific, the USA and Europe.

Karen was previously President Asia Pacific/Middle East at ResMed, and Global Vice President at Johnson & Johnson, based in the USA. She has worked for Revlon in Eastern Europe, Seagram in Russia, Goodman Fielder and Nestle in Australia and Taiwan.

Karen has recently completed a term as Chief Executive Officer of Healthdirect Australia. Prior to this, Karen was the inaugural CEO of Jobs for NSW, where she led a combined private/public sector department that redesigned government support for private enterprise.

Karen holds a Bachelor of Arts from the University of Sydney and was a NSW finalist for Telstra Businesswoman of the Year 2017. Karen was also a member of the NSW Export Advisory Council.

For further information please contact

Corporate

Mr. Neil Verdal-Austin

CEO SomnoMed

+61 406 931 477

Nverdal-austin@somnomed.com

Investors

Mr. Craig Sainsbury

Market Eye

+61 428 550 499

Craig.sainsbury@marketeye.com.au

Ms. Stephanie Ottens

Market Eye

+61 434 405 400

Stephanie.ottens@marketeye.com.au

About SomnoMed

SomnoMed is a public company providing treatment solutions for sleep-related breathing disorders including obstructive sleep apnea, snoring and bruxism. SomnoMed was commercialized on the basis of extensive clinical research. Supporting independent clinical research, continuous innovation and instituting medical manufacturing standards has resulted in SomnoDent[®] becoming the state-of-the-art and clinically proven medical oral appliance therapy for more than 580,000 patients in 28 countries. For additional information, visit SomnoMed at <http://www.somnomed.com.au>

Authorised for release to the ASX by Terry Flitcroft, Company Secretary on behalf of the Board of Directors